Pharmacologic management of neuropsychiatric lupus

作者：Kivity Shaye; Baker Britain; Arango Maria Teresa; Chapman Joab; Shoenfeld Yehuda^*

来源：Expert Review of Clinical Pharmacology, 2016, 9(1): 103-108.

DOI：10.1586/17512433.2016.1111137

• Anti-ribosomal P antibodies
• cyclophosphamide
• depression
• neuropsychiatric lupus
• systemic lupus erythematosus

Neuropsychiatric lupus affects above 50% of patients with systemic lupus erythematosus and may span from mild symptoms to acute devastating life-threatening ones. Owing to the clinical variability, most pharmacological data rely on small, uncontrolled trials and case reports. The mainstay of therapy relies on immune-suppression by glucocorticoids, in adjunction with cyclophosphamide or anti-B-cell therapy, in moderate to severe cases. In selected scenarios (e.g., chorea) intravenous immunoglobulin or plasmapheresis may be effective. Anticoagulation is warranted if anti-phospholipid antibodies are present. In parallel there may be a need for symptomatic treatment such as anti-epileptic or anti-depressive treatments, etc. In the future, more studies addressed to assess pathogenesis and preferred treatments of specific manifestations are needed in order to personalize treatments.

• 出版日期2016-1-2